LCE6A: A Potential Drug Target for Various Diseases (G448835)

Target Name: LCE6A

NCBI ID: G448835

LCE6A

Other Name(s): C1orf44 | Late cornified envelope 6A | LCE6A_HUMAN | late cornified envelope 6A | Late cornified envelope protein 6A

LCE6A: A Potential Drug Target for Various Diseases

LCE6A (C1orf44), a 61-kDa hydrophobic glycoprotein, is expressed in a variety of tissues and organs. The expression pattern of LCE6A is closely related to the occurrence and development of various diseases, such as tumors, cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, etc.

In recent years, LCE6A has received extensive attention and research as a potential drug target. Many studies have shown that the up-regulation of LCE6A expression in tumor cells is closely related to tumor invasion, metastasis and metabolism. In addition, LCE6A is also closely related to the onset and development of cardiovascular diseases, such as atherosclerotic plaque formation, myocardial infarction, hypertension, etc. In the nervous system, LCE6A is also closely related to neuronal apoptosis, synaptic plasticity and the occurrence of neurodegenerative diseases.

As a glycoprotein, LCE6A plays an important role in the occurrence and development of various diseases. The expression pattern of LCE6A is closely related to the occurrence and development of tumors, cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, etc. Therefore, LCE6A is regarded as a potential drug target and has received extensive attention and research. Future research will continue to further explore the mechanism of LCE6A in disease and explore its potential in clinical applications.

Protein Name: Late Cornified Envelope 6A

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets